Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 102

    1.

    R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature.

    Siddhartha G, Vijay P.

    J Hematol Oncol. 2009 Mar 24;2:14. Review.

    PMID:
    19309523
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

    Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, Offner FC, Gomez-Codina J, Belch A, Cunningham D, Wassner-Fritsch E, Stein G.

    J Clin Oncol. 2008 Oct 1;26(28):4579-86. Epub 2008 Jul 28.

    PMID:
    18662969
    [PubMed - indexed for MEDLINE]
    3.

    Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

    Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, Unterhalt M.

    Blood. 2005 Dec 1;106(12):3725-32. Epub 2005 Aug 25.

    PMID:
    16123223
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

    Plosker GL, Figgitt DP.

    Drugs. 2003;63(8):803-43. Review.

    PMID:
    12662126
    [PubMed - indexed for MEDLINE]
    5.

    Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.

    Jäeger G, Neumeister P, Brezinschek R, Höfler G, Quehenberger F, Linkesch W, Sill H.

    Eur J Haematol. 2002 Jul;69(1):21-6.

    PMID:
    12270058
    [PubMed - indexed for MEDLINE]
    6.

    Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.

    Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, Storti S, Lauta VM, Guardigni L, Gentilini P, Tucci A, Molinari AL, Gobbi M, Falini B, Fattori PP, Ciccone F, Alinari L, Martelli M, Pileri S, Tura S, Baccarani M.

    J Clin Oncol. 2004 Jul 1;22(13):2654-61. Epub 2004 May 24.

    PMID:
    15159414
    [PubMed - indexed for MEDLINE]
    7.

    Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.

    Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B, Basi S, Imrie K, Gascoyne RD, Sussman J, Chen BE, Djurfeldt M, Shepherd L, Couban S, Crump M.

    J Clin Oncol. 2011 Sep 1;29(25):3396-401. Epub 2011 Aug 1.

    PMID:
    21810681
    [PubMed - indexed for MEDLINE]
    8.

    Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.

    Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA.

    J Clin Oncol. 2005 Mar 1;23(7):1500-6. Epub 2005 Jan 4.

    PMID:
    15632411
    [PubMed - indexed for MEDLINE]
    9.

    Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

    Ioakimidis L, Patterson CJ, Hunter ZR, Soumerai JD, Manning RJ, Turnbull B, Sheehy P, Treon SP.

    Clin Lymphoma Myeloma. 2009 Mar;9(1):62-6.

    PMID:
    19362976
    [PubMed - indexed for MEDLINE]
    10.

    Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

    Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI; Southwest Oncology Group.

    J Clin Oncol. 2006 Sep 1;24(25):4143-9. Epub 2006 Aug 8.

    PMID:
    16896003
    [PubMed - indexed for MEDLINE]
    11.

    Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

    van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van't Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A.

    Blood. 2006 Nov 15;108(10):3295-301. Epub 2006 Jul 27.

    PMID:
    16873669
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma.

    Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P.

    Blood. 2005 Feb 15;105(4):1417-23. Epub 2004 Oct 19.

    PMID:
    15494430
    [PubMed - indexed for MEDLINE]
    Free Article
    13.

    Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.

    Jacobs SA, Swerdlow SH, Kant J, Foon KA, Jankowitz R, Land SR, DeMonaco N, Joyce J, Osborn JL, Evans TL, Schaefer PM, Luong TM.

    Clin Cancer Res. 2008 Nov 1;14(21):7088-94.

    PMID:
    18981007
    [PubMed - indexed for MEDLINE]
    Free Article
    14.

    A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.

    Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI.

    Blood. 2003 Sep 1;102(5):1606-12. Epub 2003 May 8.

    PMID:
    12738671
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma.

    Dundar Y, Bagust A, Hounsome J, McLeod C, Boland A, Davis H, Walley T, Dickson R.

    Health Technol Assess. 2009 Jun;13 Suppl 1:23-8.

    PMID:
    19567210
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    Aggressive lymphoma: improving treatment outcome with rituximab.

    Coiffier B, Pfreundschuh M, Stahel R, Vose J, Zinzani PL.

    Anticancer Drugs. 2002 Nov;13 Suppl 2:S43-50.

    PMID:
    12710590
    [PubMed - indexed for MEDLINE]
    18.

    Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.

    Tomita N, Kodama F, Oshima R, Hashimoto C, Koharazawa H, Takemura S, Yamazaki E, Fujimaki K, Sakai R, Fujita H, Fujisawa S, Kanamori H, Motomura S, Ishigatsubo Y.

    Leuk Lymphoma. 2006 Jun;47(6):1041-7.

    PMID:
    16840195
    [PubMed - indexed for MEDLINE]
    19.

    Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

    Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W.

    J Clin Oncol. 2005 Mar 20;23(9):1984-92. Epub 2005 Jan 24.

    PMID:
    15668467
    [PubMed - indexed for MEDLINE]
    20.

    Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.

    Domingo-Domènech E, González-Barca E, Estany C, Sureda A, Besalduch J, Fernández de Sevilla A.

    Haematologica. 2002 Nov;87(11):1229-30.

    PMID:
    12414357
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk